Serum Levels of Matrix Metalloproteinase 3 (Stromelysin 1) for Monitoring Synovitis in Rheumatoid Arthritis

2007 ◽  
Vol 131 (4) ◽  
pp. 563-570
Author(s):  
Ari Kobayashi ◽  
Satoko Naito ◽  
Hiroyuki Enomoto ◽  
Takayuki Shiomoi ◽  
Tokuhiro Kimura ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Matrix Metalloproteinase ◽  
White Blood Cells ◽  
Serum Levels ◽  
Cartilage Destruction ◽  
Serum Samples ◽  
Tissue Samples ◽  
Matrix Metalloproteinase 3 ◽  
Reactive Protein ◽  
Synovial Tissues

Abstract Context.—Matrix metalloproteinase 3 (MMP-3) is expressed in synovial tissues and involved in cartilage destruction in rheumatoid arthritis and osteoarthritis. Objective.—To study whether measurement of MMP-3 serum concentrations is useful to monitor the activity of rheumatoid synovitis. Design.—Levels of MMP-3 in serum and synovial tissue samples obtained from 29 rheumatoid arthritis patients and 20 osteoarthritis patients were measured by the 1-step sandwich enzyme immunoassay system. Results.—Levels of MMP-3 in the serum and synovial samples were significantly higher in rheumatoid arthritis than in osteoarthritis (P < .001), and the levels correlated directly with each other (r = 0.712, P < .001; N = 49). Immunohistochemistry demonstrated almost exclusive localization of MMP-3 to the lining cells in rheumatoid synovium. The immunoreactivity correlated directly with the scores of synovial inflammatory cell infiltration (r = 0.606, P < .001; n = 29) and the MMP-3 levels in the synovial tissues (r = 0.564, P = .001; n = 29) and those in the serum samples (r = 0.529, P = .003; n = 29) in rheumatoid arthritis. Levels of MMP-3 in rheumatoid serum samples dropped to low values at 1 and 2 weeks after total knee arthroplasty, while the levels of C-reactive protein increased at 1 week and the erythrocyte sedimentation rate and counts of white blood cells and platelets were unchanged at 1 and 2 weeks postoperative. Conclusions.—Our results demonstrate that MMP-3 levels in the serum of rheumatoid arthritis patients correlate with the levels produced by the synovial lining cells and suggest that the activity of rheumatoid synovitis can be monitored by measuring serum levels of MMP-3.

scholarly journals The influence of tocilizumab immunogenicity markers on the effectiveness of treating rheumatoid arthritis

2020 ◽  
Vol 12 (1) ◽  
pp. 31-36
Author(s):  
Vladimir D. Nazarov ◽  
Sergey V. Lapin ◽  
Ksenia V. Tulenko ◽  
Rusana R. Samigullina ◽  
Vadim I. Mazurov
Keyword(s):  
Rheumatoid Arthritis ◽  
White Blood Cells ◽  
Serum Levels ◽  
Patient Visit ◽  
Drug Injection ◽  
C Reactive Protein ◽  
Serum Samples ◽  
Reactive Protein ◽  
Positive Correlations ◽  
The Impact

Purpose. The study assesses the impact of tocilizumab immunogenicity markers on clinical response to conducted treatment in patients with rheumatoid arthritis. Materials and methods. A total of 17 patients with the confirmed diagnosis of RA receiving tocilizumab therapy for more than 1 year were enrolled into the study. Blood serum samples were collected once every six months before every drug injection during 2.5 years of treatment. The concentration of antibodies to tocilizumab and level of tocilizumab was determined using the ELISA. Additionally, DAS28 values were measured at the first and the last patient visit during the course of study, whereas levels of C-reactive protein (CRP), white blood cells, platelets, rheumatoid factor, and circulating immune complexes were only measured at the last examination. Results. Positive correlations between the antibodies to tocilizumab and the last point DAS28 values were found, as well as a negative correlation of tocilizumab level and the level of DAS28. Conclusions. The data obtained indicate a significant effect of serum levels of tocilizumab, as well as of the concentration of antibodies to tocilizumab on the effectiveness of RA treatment. A routine study of these biomarkers might be useful for individualizing treatment approaches for RA patients and determining the causes of tocilizumab resistance.

scholarly journals Serum and synovial fluid levels of matrix metalloproteinase-3 as a biomarker of joint damage in patients with rheumatoid arthritis

QJM ◽  
2020 ◽  
Vol 113 (Supplement_1) ◽  
Author(s):  
E A Hafez ◽  
S A Elbakry ◽  
M A Abdelrahman ◽  
H M Sakr ◽  
N A Mohamed ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Matrix Metalloproteinase ◽  
Disease Activity ◽  
Healthy Volunteers ◽  
Joint Damage ◽  
Serum Levels ◽  
Common Disease ◽  
Special Role ◽  
Matrix Metalloproteinase 3 ◽  
Early Ra

Abstract Background Rheumatoid arthritis (RA) is one of the systemic autoimmune diseases characterized by chronic synovitis and progressive joint destruction leading to decline in functional capacity, eventual work disability, and reduced quality of life. Considering the common disease activity indicators are unspecific for arthritis, novel biomarkers have been rapidly developed for predicting structural destruction progression in RA. Matrix metalloproteinase-3 plays a special role in rheumatoid arthritis pathogenesis and has been suggested as a marker of disease activity and joint damage. Patients and Methods MMP-3 was measured by ELISA in serum samples of 40 early RA patients and compared to age and sex matched control group of 40 healthy volunteers. Synovial levels of MMP-3 were measured only in 8 RA patients, who were indicated for knee arthrocentesis. Joint damage was assessed using SENS score on plain radiography. Results Serum MMP-3 levels were significantly higher in RA patients than healthy volunteers (P-value <0.001). Measured synovial levels of MMP-3 were significantly correlated to the serum levels. There were statistically significant positive correlations between serum MMP-3 with RF titers, AntiCCP titres, CRP, and DAS28 -ESR activity score. There was no significant correlation to total SENS score. ROC curve was used to define the best cut off value of serum MMP3 to discriminate between RA and healthy controls, which was found to be >50ng/ml. Conclusion Serum levels of MMP-3 can be used as noninvasive biomarker of RA, and also indicator of disease activity in early RA patients.

scholarly journals Effect of Moxibustion on the Serum Levels of MMP-1, MMP-3, and VEGF in Patients with Rheumatoid Arthritis

2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
Zeyun Yu ◽  
Yingni Wang ◽  
Yuan Li ◽  
Chenxi Liao ◽  
Jingyang Dai ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Treatment Group ◽  
Matrix Metalloproteinase ◽  
Clinical Symptoms ◽  
Interleukin 1 ◽  
Serum Levels ◽  
Control Group ◽  
Matrix Metalloproteinase 3 ◽  
Disease Markers ◽  
Matrix Metalloproteinase 1

Background. Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease, which will eventually lead to joints deformity and functional damage. The aim of this research is to evaluate the effect of moxibustion on the serum indicators related to bone and cartilage metabolism, matrix metalloproteinase 1 (MMP-1), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) in patients with RA and to explore the mechanism of moxibustion in the treatment of RA. Methods. We recruited 70 RA patients who met the inclusion criteria, and they were randomly divided into two groups, a treatment group and a control group in equal ratio. The control group took methotrexate, folate, or leflunomide orally, while the treatment group received methotrexate, folate, or leflunomide orally and moxibustion at ST36 (Zusanli), BL23 (Shen shu), and Ashi points. We compared the clinical symptoms, RA serological disease markers and serum contents of interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), MMP-1, MMP-3, and VEGF of RA patients before and after treatment. Results. (1) The clinical symptoms and RA serological disease markers of the two groups improved after treatment (P < 0.05), while the clinical symptoms of the treatment group were significantly improved in comparison with the control group (P < 0.05). (2) The levels of IL-1β, TNF-α, and VEGF decreased in both groups after treatment (P < 0.05), but the treatment group was significantly decreased compared with the control group (P < 0.05). (3) There were significant differences in MMP-1 and MMP-3 contents after treatment in the treatment group (P < 0.05, P < 0.05), while there were no significant differences in the control group (P > 0.05, P > 0.05). Above all, the contents of IL-1β, TNF-α, MMP-1, MMP-3, and VEGF in the treatment group decreased more significantly than those in the control group (P < 0.05). Conclusion. The improvement effect of moxibustion on the clinical symptoms of RA patients may be related to influence on the contents of IL-1β, TNF-α, MMP-1, MMP-3, and VEGF, and moxibustion may play a potential role in bone protection.

Sign in / Sign up

Export Citation Format

Share Document